Federal Register Notice: FDA is making available additional draft and revised draft product-specific bioequivalence (BE) recommendations to support ANDAs. The recommendations are for products including avanafil, buprenorphine hydrochloride, deferiprone, flucinolone acetonide, and naproxen sodium. To view this notice, click here.
